# The Rifaximin Study in CVID

> **NCT01946906** · PHASE4 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 40 (actual)

## Conditions studied

- Common Variable Immunodeficiency (CVID)

## Interventions

- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT01946906
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946906, "The Rifaximin Study in CVID". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01946906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*